Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Editorial

Dare to fail greatly
March issue editorial by editor Thierry Heles.
Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Anaveon proves UZH fund model works
Anaveon emerged out of University of Zurich in late 2017 with the support of Novartis-backed UZH Life Sciences Fund and the corporate has now also invested directly.
Big deal: Nightstar shines bright in $800m acquisition
Nightstar Therapeutics, based on Oxford research, stands to receive $800m from Biogen in an acquisition deal that comes a year and a half after completing a $75m IPO.
I license, therefore I am
February 2019 issue editorial by editor Thierry Heles
Lighting the match
January 2019 issue editorial by Thierry Heles, editor, Global University Venturing
Big deal: Stanford-StartX Fund reaches the end
The Stanford University-backed fund will halt new investments from July, seemingly as the accelerator reaches financial stability but in the midst of a legal battle.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

Other News

The only way has always been up
November issue editorial by Thierry Heles, editor, Global University Venturing
Everything ventured, everything gained
Introducing the Global University Venturing Powerlist 2018
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
When the comic gets serious
October issue editorial by Thierry Heles, editor, Global University Venturing
UCL Technology Fund: an unparalleled approach to commercialisation
Editor Thierry Heles sits down with David Grimm (pictured), manager of the UCL Technology Fund, to find out what makes the fund unique among its UK and international peers.
Editorial: For the good of investors
As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Everything ventured, everything gained
Introducing the Global University Venturing Powerlist 2018
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login